Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127Skye Montoya(Sylvester Comprehensive Cancer Center), Justin Taylor(Medical University of South Carolina)ScienceFebruary 1, 202410.1126/science.adi5798Cited by 143SaveCiteExport RISWatch citationsRelated PapersPirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study|The Lancet|2021|456LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study|Blood|2020|26Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study|Blood|2021|15